Instrument Inactif

Autres langues Urovant Sciences Ltd.

Actions

UROV

BMG9381B1081

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement	05/07/22
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting	15/05/22
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints	13/05/22
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice	19/04/22
Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting	13/04/22
Urovant Sciences Announces Management Changes	04/04/22
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902	07/03/22
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg	20/12/21
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients	08/11/21
Urovant Sciences Ltd. Announces Executive Changes	26/10/21
Urovant Sciences Names Betzy Estrada as Executive VP and Chief Human Resources Officer	20/08/21
Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association	18/08/21
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from S&P TMI Index	31/03/21
UROVANT SCIENCES LTD. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	29/03/21
Urovant Sciences Ltd. Announces Board Changes	29/03/21
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from NASDAQ Composite Index	29/03/21
Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd..	29/03/21
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss	12/02/21
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21
Urovant Sciences : Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results	12/02/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Urovant Sciences Ltd.

Actions

UROV

BMG9381B1081

Autres langues

Filtres